These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 19275539)
21. Resistance to polymyxins: Mechanisms, frequency and treatment options. Falagas ME; Rafailidis PI; Matthaiou DK Drug Resist Updat; 2010; 13(4-5):132-8. PubMed ID: 20843473 [TBL] [Abstract][Full Text] [Related]
22. Bacterial surface appendages as targets for novel antibacterial therapeutics. Steadman D; Lo A; Waksman G; Remaut H Future Microbiol; 2014; 9(7):887-900. PubMed ID: 25156378 [TBL] [Abstract][Full Text] [Related]
23. Antibiotics in the clinical pipeline in 2011. Butler MS; Cooper MA J Antibiot (Tokyo); 2011 Jun; 64(6):413-25. PubMed ID: 21587262 [TBL] [Abstract][Full Text] [Related]
24. Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens? Domalaon R; Idowu T; Zhanel GG; Schweizer F Clin Microbiol Rev; 2018 Apr; 31(2):. PubMed ID: 29540434 [TBL] [Abstract][Full Text] [Related]
25. New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria. O'Neill AJ Expert Opin Investig Drugs; 2008 Mar; 17(3):297-302. PubMed ID: 18321229 [TBL] [Abstract][Full Text] [Related]
26. Disrupting Gram-Negative Bacterial Outer Membrane Biosynthesis through Inhibition of the Lipopolysaccharide Transporter MsbA. Alexander MK; Miu A; Oh A; Reichelt M; Ho H; Chalouni C; Labadie S; Wang L; Liang J; Nickerson NN; Hu H; Yu L; Du M; Yan D; Park S; Kim J; Xu M; Sellers BD; Purkey HE; Skelton NJ; Koehler MFT; Payandeh J; Verma V; Xu Y; Koth CM; Nishiyama M Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104274 [TBL] [Abstract][Full Text] [Related]
27. Lipid a biosynthesis of multidrug-resistant pathogens - a novel drug target. Lee CR; Lee JH; Jeong BC; Lee SH Curr Pharm Des; 2013; 19(36):6534-50. PubMed ID: 23829374 [TBL] [Abstract][Full Text] [Related]
28. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery. Schweizer HP Expert Opin Drug Discov; 2012 Jul; 7(7):633-42. PubMed ID: 22607346 [TBL] [Abstract][Full Text] [Related]
29. Mechanism and Potential Inhibitors of GlmU: A Novel Target for Antimicrobial Drug Discovery. Sharma R; Khan IA Curr Drug Targets; 2017; 18(14):1587-1597. PubMed ID: 27138757 [TBL] [Abstract][Full Text] [Related]
31. De novo designed lipopolysaccharide binding peptides: structure based development of antiendotoxic and antimicrobial drugs. Bhattacharjya S Curr Med Chem; 2010; 17(27):3080-93. PubMed ID: 20629624 [TBL] [Abstract][Full Text] [Related]
33. Disarming the invader. Young GM Chem Biol; 2003 Mar; 10(3):204-5. PubMed ID: 12670533 [TBL] [Abstract][Full Text] [Related]
34. Will new antimicrobials overcome resistance among Gram-negatives? Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303 [TBL] [Abstract][Full Text] [Related]
35. Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses. Troudi A; Pagès JM; Brunel JM J Med Chem; 2021 Feb; 64(4):1816-1834. PubMed ID: 33538159 [TBL] [Abstract][Full Text] [Related]
36. Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective. Alibert S; N'gompaza Diarra J; Hernandez J; Stutzmann A; Fouad M; Boyer G; Pagès JM Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):301-309. PubMed ID: 27764576 [TBL] [Abstract][Full Text] [Related]
37. Structure-based discovery of LpxC inhibitors. Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397 [TBL] [Abstract][Full Text] [Related]
38. [The history of the development and changes of quinolone antibacterial agents]. Takahashi H; Hayakawa I; Akimoto T Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768 [TBL] [Abstract][Full Text] [Related]
39. The development of efflux pump inhibitors to treat Gram-negative infections. Blanco P; Sanz-García F; Hernando-Amado S; Martínez JL; Alcalde-Rico M Expert Opin Drug Discov; 2018 Oct; 13(10):919-931. PubMed ID: 30198793 [TBL] [Abstract][Full Text] [Related]
40. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Briers Y; Lavigne R Future Microbiol; 2015; 10(3):377-90. PubMed ID: 25812461 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]